David Lebovitz
Stock Analyst at Citigroup
(3.39)
# 1,008
Out of 5,045 analysts
91
Total ratings
68.18%
Success rate
10.58%
Average return
Main Sectors:
Top Industries:
Stocks Rated by David Lebovitz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $527 → $583 | $454.30 | +28.33% | 33 | Sep 2, 2025 | |
| BMRN BioMarin Pharmaceutical | Maintains: Neutral | $82 → $78 | $52.23 | +49.34% | 4 | May 2, 2025 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Buy | $378 → $469 | $421.18 | +11.35% | 4 | Feb 27, 2025 | |
| CRNX Crinetics Pharmaceuticals | Maintains: Buy | $70 → $74 | $42.99 | +72.13% | 2 | Nov 14, 2024 | |
| MIRM Mirum Pharmaceuticals | Maintains: Buy | $37 → $38 | $72.19 | -47.36% | 1 | May 9, 2024 | |
| PTCT PTC Therapeutics | Downgrades: Sell | $29 → $17 | $68.14 | -75.05% | 5 | Oct 27, 2023 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Overweight | $57 → $54 | $110.00 | -50.91% | 5 | Aug 4, 2021 | |
| IONS Ionis Pharmaceuticals | Maintains: Underweight | $38 → $35 | $75.09 | -53.39% | 6 | May 6, 2021 | |
| MGNX MacroGenics | Maintains: Underweight | $16 → $17 | $1.63 | +942.94% | 11 | Apr 30, 2021 | |
| IRWD Ironwood Pharmaceuticals | Maintains: Equal-Weight | $12 → $11 | $1.68 | +556.72% | 7 | Feb 22, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $194 → $199 | $201.95 | -1.46% | 11 | Nov 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $510 → $480 | $5.81 | +8,161.62% | 2 | Nov 3, 2020 |
Alnylam Pharmaceuticals
Sep 2, 2025
Maintains: Buy
Price Target: $527 → $583
Current: $454.30
Upside: +28.33%
BioMarin Pharmaceutical
May 2, 2025
Maintains: Neutral
Price Target: $82 → $78
Current: $52.23
Upside: +49.34%
Madrigal Pharmaceuticals
Feb 27, 2025
Maintains: Buy
Price Target: $378 → $469
Current: $421.18
Upside: +11.35%
Crinetics Pharmaceuticals
Nov 14, 2024
Maintains: Buy
Price Target: $70 → $74
Current: $42.99
Upside: +72.13%
Mirum Pharmaceuticals
May 9, 2024
Maintains: Buy
Price Target: $37 → $38
Current: $72.19
Upside: -47.36%
PTC Therapeutics
Oct 27, 2023
Downgrades: Sell
Price Target: $29 → $17
Current: $68.14
Upside: -75.05%
Rhythm Pharmaceuticals
Aug 4, 2021
Maintains: Overweight
Price Target: $57 → $54
Current: $110.00
Upside: -50.91%
Ionis Pharmaceuticals
May 6, 2021
Maintains: Underweight
Price Target: $38 → $35
Current: $75.09
Upside: -53.39%
MacroGenics
Apr 30, 2021
Maintains: Underweight
Price Target: $16 → $17
Current: $1.63
Upside: +942.94%
Ironwood Pharmaceuticals
Feb 22, 2021
Maintains: Equal-Weight
Price Target: $12 → $11
Current: $1.68
Upside: +556.72%
Nov 13, 2020
Maintains: Overweight
Price Target: $194 → $199
Current: $201.95
Upside: -1.46%
Nov 3, 2020
Maintains: Overweight
Price Target: $510 → $480
Current: $5.81
Upside: +8,161.62%